Verici Dx plc (VRCDF) Stock Price & Analysis
Verici Dx plc (VRCDF) — price $0.003 (0.00%), as of the Oct 2, 2026 trading session; market cap $6.86M.
Educational signal · not a buy or sell recommendation · How to read this
Verici Dx plc · VRCDF
Verici Dx plc is an immuno-diagnostics development company focused on the kidney transplantation market. The company is developing prognostic and diagnostic tests, including Clarava, Tuteva, and Protega, to improve outcomes for kidney transplant patients.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.003 |
| Change on the day | 0.00% |
| Market capitalisation | $6.86M |
| Shares traded on the day | 200 |
Price & events
Other perspectives
Council score for Verici Dx (VRCDF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the VRCDF film — every key number, told as a short cinematic story
~2 min · open the film
What is Verici Dx (VRCDF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Verici Dx plc (VRCDF) is the company analyzed here. It employs 18 people. In Q4 FY2025 it reported revenue of $2M and net income of -$4M. The market values it at $6.86M.
What do the latest results show for Verici Dx (VRCDF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $2M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $2M | -$4M | -$0.0026 (diluted) |
| Q2 FY2025 | $2M | -$3M | -$0.01 (diluted) |
| Q4 FY2024 | $0 | -$4M | -$0.02 (diluted) |
| Q2 FY2024 | $3M | -$1M | -$0.01 (diluted) |
What are the financial strengths and risks for Verici Dx (VRCDF)?
Short answer
The distress and quality screens read Altman Z -9.05 · Piotroski F 3. Trailing ratios: ROA -78.6% · current ratio 3.94 · earnings yield -138.4%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -9.05 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Verici Dx (VRCDF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $4.89M · EPS -0.00 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $4.89M
- EPS estimate
- $-0.00
Measured against a quoted price of $0.003 (as of Oct 2, 2026).
Verici Dx Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the VRCDF research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What is the current status of Verici Dx plc's diagnostic pipeline?
Verici Dx plc's diagnostic pipeline consists of three key in-development tests. Clarava is a pre-transplant prognosis test focused on the risk of early acute rejection. Tuteva is a post-transplant test designed to detect acute cellular rejection. Protega is an innovative liquid biopsy aiming to predict the risk of fibrosis and long-term graft failure.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.003 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T10:45:02.015Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.86M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T10:45:01.007Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 200 | FMP | Financial Modeling Prep (FMP) · quote | |
id.employees | Employees | 18 | FMP | Financial Modeling Prep (FMP) · company profile — Captured 2026-10-03 | |
fin.q_revenue | Revenue, Q4 FY2025 | $2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2025 | -$4M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z -9.05 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-08-13 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -78.6% · current ratio 3.94 · earnings yield -138.4% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $4.89M · EPS -0.00 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-07-03 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $4.89M | UNRECORDED | Stored analyst estimates — Captured 2026-07-03 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-0.00 | UNRECORDED | Stored analyst estimates — Captured 2026-07-03 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.